



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/519,594

12/28/2004

David Cavalla

GJE-6758

2624

23557 7590 05/31/2007
SALIWANCHIK LLOYD & SALIWANCHIK
A PROFESSIONAL ASSOCIATION
PO BOX 142950
GAINESVILLE, FL 32614-2950

EXAMINER

SOROUGH, LAYLA

ART UNIT

PAPER NUMBER

1617

MAIL DATE

DELIVERY MODE

05/31/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/519,594	Applicant(s) CAVALLA ET AL.	
	Examiner Layla Soroush	Art Unit 1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 01 January 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-7 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-7 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

The response filed January 1, 2007 presents remarks and arguments submitted to the office action mailed July 27, 2006 is acknowledged.

Applicant's arguments over the 35 U.S.C. 103 (a) rejection of claims 1-7 over Ninomiya et al. (US Pat. No. 4,695,568 –IDS), in view of Davies et al. (US Pat. No. 6,008227) is persuasive. Therefore, the rejection is withdrawn.

Since Applicant has not put forth any arguments against the 35 USC 101 (Statutory Double Patenting Rejection) of claims 1-7 over copending application no. 10/617847 the rejection is maintained.

The following new rejections are made:

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ninomiya et al. (US Pat. No. 4,695,568 –IDS), in view of McNally et al. (PCT/SE98/00641 English equivalent US Pat. No. 6,303,613).

Ninomiya et al. teaches a 4-(2-Fluorophenyl)-6-methyl-2-(1-piperaziny)thieno[2,3-D]pyrimidine monohydrate hydrochloride in treatment of various depressions (see abstract; column 4, lines 9-11).

Art Unit: 1617

Ninomiya et al. fails to teach the treatment of irritable bowel syndrome.

McInally et al. teaches especially preferred embodiments are where the compound of formula (I) is a thieno[2,3-d]pyrimidine or a thieno[3,2-d]pyrimidine (column 3, line 13-15). The compounds "are indicated for use in the treatment of inflammatory conditions in mammals, including man. Conditions that may be specifically mentioned" are inclusive of osteoarthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis and other arthritic conditions, inflamed joints, pain, acute or persistent inflammatory or neuropathic pain or pain of a central origin (nociceptive or neuropathic), conditions of the gastrointestinal tract such as irritable bowel syndrome (column 8, line 23-25, 38, and 40-45), and depression (column 9 line 8 and 9).

Therefore, it would have been obvious to one of ordinary skill in the art to use the identical compound in treating irritable bowel syndrome. The motivation to use 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine to treat irritable bowel syndrome is because the teachings in McInally et al. that analogues of thieno[2,3-d]pyrimidine compounds are indicated for use in the treatment of inflammatory conditions in mammals, including man. Conditions that may be specifically mentioned are inclusive of conditions of the gastrointestinal tract such as irritable bowel syndrome (column 8, line 23-25, 38, and 40-45)), and depression (column 9 line 8 and 9). The skilled artisan would have reasonable expectation of successfully treating irritable bowel syndrome using the drug 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine.

Art Unit: 1617

Additionally, because the reference teaches the genus irritable bowel syndrome, the species diarrhea-predominant irritable bowel syndrome, alternating constipation/diarrhea irritable bowel syndrome, and constipation-predominant irritable bowel syndrome of claims 8, 10, and 11 are rendered obvious by the teachings of the prior art. The reference teaches patients in general, therefore, the limitation of claim 9, "wherein the patient is female" is rendered obvious by the prior art.

Double Patenting

A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101.

Claims 1-7 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 5-11 of copending Application No. 10/617847. This is a provisional double patenting rejection since the conflicting claims have not in fact been patented.

Response to Arguments

Applicant's arguments January 1, 2007 have been fully considered but they are not persuasive for the reasons set forth below.

Applicant's arguments regarding the Ninomiya et al. reference provides no basis for concluding 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine monohydrate hydrochloride is an effective anti-depressant is not persuasive. In particular, claims 17 and 18 are drawn to the pharmaceutical for improving the depressive conditions and/or dysfunction of the brain. However the arguments with respect to the Davies et al. (US Pat. No. 6,008,227) have been considered and are persuasive. In view of the new ground(s) of rejection the applicant's arguments are moot.

The 35 U.S.C. 101 rejection over U.S. Patent Application No. 10/617,847 will be withdrawn upon either the cancellation or amendment of claims in application 10/617,847.

Conclusion

No claims allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Layla Soroush whose telephone number is (571)272-5008. The examiner can normally be reached on Monday through Friday from 8:30 a.m. to 5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan, can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information

Art Unit: 1617

for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

A handwritten signature in black ink, appearing to read "S. Wang".

SHENGJUN WANG
PRIMARY EXAMINER